Company intelligence / Profile preview
Zaiding Pharmaceutical
- Ownership
- Private
- Employees
- ~700
- Development stage
- Commercial
Overview
Zaiding Pharmaceutical is a leading Chinese biopharmaceutical company focused on innovative therapies for cancer, autoimmunity, and infectious diseases. It has built one of the strongest advanced cancer pipelines among Chinese biotech companies through internal R&D and global partnerships. Its most advanced asset is REGN1979—a bispecific monoclonal antibody targeting CD20 and CD3—currently in Phase II trials for B-cell non-Hodgkin lymphoma. The company aims to file 1–2 global INDs annually and has robust capabilities spanning discovery to commercialization.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific monoclonal antibodySmall molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Zaiding Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zaiding Pharmaceutical.